Added to YB: 2025-09-16
Pitch date: 2025-09-12
NOVO-B.CO [neutral]
Novo Nordisk A/S
-8.24%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 350.00
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
turnaround
Theodosian Capital | NOVOB – Restructuring
NOVO-B.CO (update): Restructuring cuts 9,000 jobs (11.5% of workforce) to save DKK8bn annually by end-2026; DKK8bn one-off charge. FY op profit growth 4-10% post-charge. Headcount grew 70% since 2020, costs too fast. Trading 13.1x 2026 consensus earnings, 3.9% yield. Quality entry point.
Read full article (1 min)